268 related articles for article (PubMed ID: 10639319)
1. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
[TBL] [Abstract][Full Text] [Related]
3. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
4. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
5. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
6. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.
Aldaz-Carroll L; Whitbeck JC; Ponce de Leon M; Lou H; Pannell LK; Lebowitz J; Fogg C; White CL; Moss B; Cohen GH; Eisenberg RJ
Virology; 2005 Oct; 341(1):59-71. PubMed ID: 16083934
[TBL] [Abstract][Full Text] [Related]
7. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
8. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
9. Extracellular enveloped vaccinia virus escapes neutralization.
Ichihashi Y
Virology; 1996 Mar; 217(2):478-85. PubMed ID: 8610439
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
Vanderzanden L; Bray M; Fuller D; Roberts T; Custer D; Spik K; Jahrling P; Huggins J; Schmaljohn A; Schmaljohn C
Virology; 1998 Jun; 246(1):134-44. PubMed ID: 9657001
[TBL] [Abstract][Full Text] [Related]
12. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
Gurt I; Abdalrhman I; Katz E
Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
[TBL] [Abstract][Full Text] [Related]
13. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
Raviprakash K; Marques E; Ewing D; Lu Y; Phillips I; Porter KR; Kochel TJ; August TJ; Hayes CG; Murphy GS
Virology; 2001 Nov; 290(1):74-82. PubMed ID: 11883007
[TBL] [Abstract][Full Text] [Related]
14. The exit of vaccinia virus from infected cells.
Smith GL; Law M
Virus Res; 2004 Dec; 106(2):189-97. PubMed ID: 15567497
[TBL] [Abstract][Full Text] [Related]
15. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
18. A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge.
Ganges L; Barrera M; Núñez JI; Blanco I; Frias MT; Rodríguez F; Sobrino F
Vaccine; 2005 May; 23(28):3741-52. PubMed ID: 15882536
[TBL] [Abstract][Full Text] [Related]
19. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
